SCHEMBL3835529

SCHEMBL3835529

CCOC(=O)[C@@H](N)Cc1cc(OC)c(-c2ccccc2)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPH1 P17752 4/20 0.45
SCN9A Q15858 1/20 0.44
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
GRM6 O15303 1/20 0.41
OPRK1 P41145 1/20 0.41
HK2 P52789 1/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40
ITGB7 P26010 1/20 0.40
LDHA P00338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3833206 0.90 ALDH1A1 (0.51) TPH1ALDH1A1OPRK1HK2SMN1; SMN2
SCHEMBL2991512 0.87 SLC7A5 (0.54) TPH1LDHA
SCHEMBL919730 0.85 TPH1 (0.52) TPH1SCN9AALDH1A1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL27504082 0.84 TPH1 (0.53) TPH1SCN9AALDH1A1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL919728 0.84 TPH1 (0.53) TPH1SCN9AALDH1A1LMNASMN1; SMN2
SCHEMBL1021631 0.83 TPH1 (0.51) TPH1SCN9AALDH1A1LMNASMN1; SMN2
SCHEMBL918869 0.83 TPH1 (0.51) TPH1SCN9AALDH1A1LMNASMN1; SMN2
SCHEMBL1022271 0.83 TPH1 (0.51) TPH1SCN9AALDH1A1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL918867 0.82 TPH1 (0.52) TPH1SCN9AALDH1A1LMNASMN1; SMN2
SCHEMBL4648020 0.80 TPH1 (0.48) TPH1SCN9AALDH1A1HPGDITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501437-B2 Phenylalanine enamide derivatives UCB PHARMA, S.A. (BE) 2009-03-10 US disclosed
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders UCB PHARMA S.A. (BE) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders ITGB2, VCAM1, ITGB1 TPH1 1034/4885SCN9A 1524/4885ALDH1A1 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.